Annals of Hematology

, Volume 97, Issue 4, pp 741–742 | Cite as

Immune thrombocytopenia induced by vonoprazan fumarate: a single center retrospective study

  • Naruko Suzuki
  • Junji Hiraga
  • Yusuke Takagi
  • Tomoyuki Tsuzuki
  • Natsuko Uematsu
  • Yoshitoyo Kagami
Letter to the Editor

Dear Editor,

Vonoprazan fumarate is a first-in-class potassium-competitive acid blocker developed in Japan. Compared with conventional proton-pump inhibitors (PPI), vonoprazan is absorbed rapidly and reaches maximum plasma concentration shortly after oral administration because activation by gastric acid is no longer required [1]. It is approved for treatment in gastroduodenal ulcers, reflux esophagitis, and Helicobacter pylori eradication [2, 3, 4]. Drugs can cause thrombocytopenia by several mechanisms, including drug-induced immune thrombocytopenia (DITP): an antibody-mediated platelet destruction caused by exposure to a drug [5]. DITP due to PPI has been described previously [6, 7, 8]; however, no studies have examined induction of thrombocytopenia by vonoprazan exposure. We report a retrospective study on immune thrombocytopenia caused by vonoprazan.

From August 2015 to December 2016, 1577 patients were administered vonoprazan for 7 days or longer in our hospital. The median age...


Compliance with ethical standards

Informed consent was obtained from the patient for publication. This study was performed in conformity with the Declaration of Helsinki and was approved by our ethical committee.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Echizen H (2016) The first-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamics considerations. Clin Pharmacokinet 55(4):409–418. CrossRefPubMedGoogle Scholar
  2. 2.
    Maruoka D, Arai M, Kasamatsu S, Ishigami H, Taida T, Okimoto K, Saito K, Matsumura T, Nakagawa T, Katsuno T, Yokosuka O (2017) Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: a propensity score-matching analysis. Dig Endosc 29(1):57–64. CrossRefPubMedGoogle Scholar
  3. 3.
    Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, Umegaki E, Iwakiri K (2016) Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 43(2):240–251. CrossRefPubMedGoogle Scholar
  4. 4.
    Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M (2016) Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 65(9):1439–1446. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Aster RH, Bougie DW (2007) Drug-induced immune thrombocytopenia. N Engl J Med 357(6):580–587. CrossRefPubMedGoogle Scholar
  6. 6.
    Kallam A, Singla A, Silberstein P (2014) Proton pump induced thrombocytopenia: a case report and review of literature. Platelets 26:598–601CrossRefPubMedGoogle Scholar
  7. 7.
    Binnetoğlu E, Akbal E, Şen H, Güneş F, Erbağ G, Aşık M, Bozkurt N, Uludağ A, Tekin M, Tekin SZ (2015) Pantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding. Platelets 26(1):10–12. CrossRefPubMedGoogle Scholar
  8. 8.
    Wilhelm SM, Rjater RG, Kale-Pradhan PB (2013) Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol 6(4):443–451. CrossRefPubMedGoogle Scholar
  9. 9.
    Kenney B, Stack G (2009) Drug-induced thrombocytopenia. Arch Pathol Lab Med 133(2):309–314. PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Hematology, Toyota Kosei HospitalToyota CityJapan
  2. 2.Department of Gastroenterology, Toyota Kosei HospitalToyotaJapan
  3. 3.Department of Pharmacology, Toyota Kosei HospitalToyotaJapan

Personalised recommendations